MLTX DEADLINE: Faruqi & Faruqi Reminds MoonLake Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 - MLTX

Core Viewpoint - The complaint against MoonLake alleges violations of federal securities laws due to false and misleading statements regarding the efficacy and structure of its drug SLK compared to monoclonal antibodies like BIMZELX [2]. Group 1: Allegations and Legal Proceedings - The complaint claims that MoonLake and its executives failed to disclose that SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [2]. - It is alleged that SLK's unique Nanobody structure does not provide a clinical benefit over BIMZELX's traditional monoclonal structure [2]. - The complaint also states that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for positive statements about SLK's superiority [2]. Group 2: Market Reaction - Following the announcement of the Phase 3 VELA program results on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy against BIMZELX, MoonLake's stock price dropped by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [3].